Search | Clinical Trials Finder

Conditions: Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
Interventions: CT Coronary Angiography (CTCA), Traditional Strategy; Diagnostic Test · Procedure
Lead sponsor: American College of Radiology; Other
Eligibility: 30 Years and older
Enrollment: 1,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more

Conditions: New Onset Atrial Fibrillation
Interventions: Not listed
Lead sponsor: St. Francis Hospital, New York; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Roslyn, New York

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 545
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more

Conditions: Coronary Disease
Interventions: placebo, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions: prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 9
States / cities: Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more

Conditions: Cardiac Arrhythmia
Interventions: Not listed
Lead sponsor: iRhythm Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Acute Coronary Syndrome
Interventions: Milvexian, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 162
States / cities: Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 7,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 267
States / cities: Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more

Conditions: Hypertension
Interventions: clevidipine, nitroglycerin; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 28
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 19 more

Conditions: Acute Coronary Syndrome, Tobacco Use
Interventions: BAT-CS, Smoking Cessation and Health & Wellness; Behavioral
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cardiovascular Complications, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: rosuvastatin, placebo, survey administration, management of therapy complications; Drug · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Acute Coronary Syndrome
Interventions: veliflapon (DG-031); Drug
Lead sponsor: deCODE genetics; Industry
Eligibility: 35 Years and older
Enrollment: 3,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 11
States / cities: Montgomery, Alabama • Jacksonville, Florida • Melrose Park, Illinois + 8 more

Conditions: ASCVD, LDL-C
Interventions: Care Champion Intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity
Interventions: Sibutramine hydrochloride, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 55 Years and older
Enrollment: 10,777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 2,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more

Conditions: Cardiovascular Disease, Cerebrovascular Disorders
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years and older
Enrollment: 26,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: ABBV-453, Dexamethasone, Daratumumab, Lenalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Stanford, California • Miami, Florida • New Orleans, Louisiana + 9 more

Conditions: Atrial Fibrillation
Interventions: Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later; Device
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 34,244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Atrial Fibrillation
Interventions: Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 162
States / cities: Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more

Conditions: Atherosclerosis
Interventions: Darapladib, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15,828 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 155
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more

Conditions: Thrombosis
Interventions: Heparin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Rochester, Minnesota • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma, Lymphoma Mantle-cell, Immunotherapy, Cell and Tissue-Based Therapy, Cytokines, Monitoring Physiologic, Immune Monitoring, Wearable Electronic Devices, Thermometry, Body Temperature, Antibodies Bispecific, Receptors Chimeric Antigen
Interventions: TempTraq, VitalTraq; Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pregnancy Complications, Cardiovascular
Interventions: Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.; Other
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Carotid Artery Stenosis
Interventions: Roadsaver™ Carotid Artery Stent Device, Nanoparasol® Embolic Protection System; Device
Lead sponsor: Microvention-Terumo, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 37
States / cities: Phoenix, Arizona • Prescott, Arizona • Los Angeles, California + 31 more

Search by objective public record fields.

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

True Continuous ECG Monitoring (TCEM Study)

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

Post Acute Cardiac Event Smoking (PACES) Study

Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study

Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis